ARTICLE | Clinical News
Racivir: Phase II data
June 18, 2007 7:00 AM UTC
In a Phase II trial, 600 mg of oral Racivir reduced viral loads by a mean of 0.7 log10 (80%) in responders with the M184V mutation and <3 thymidine analog mutations. VRUS is developing Racivir as a se...